All transcripts were created with artificial intelligence software and modified with manual review by a third party. Although we make every effort to ensure accuracy with the manual review, some may contain computer-generated mistranslations resulting in inaccurate or nonsensical word combinations, or unintentional language. FASEB and the presenting speakers did not review the transcripts and are not responsible and will not be held liable for damages, financial or otherwise, that occur as a result of transcript inaccuracies.
KMT2A-Rearranged Leukemias: Updates and Opportunities
Kathrin M. Bernt, MD
The Children’s Hospital of Philadelphia
The University of Pennsylvania
KMT2A-rearranged leukemias have long represented a therapeutic conundrum, with outcomes remaining unchanged despite an increasingly sophisticated understanding of the biology of these leukemias. Recent encouraging early phase data suggest that the incorporation of immunotherapy and targeted agents may finally act to improve survival. In this presentation, I will discuss our insights from the single cell transcriptomic and epigenomic analysis of KMT2A-rearranged infant leukemias, as well as mechanisms of resistance to both conventional chemotherapy and targeted agents.